- US-listed companies
- VERTEX PHARMACEUTICALS INC
- Income statement
VERTEX PHARMACEUTICALS INC【VRTX】Income statement
Market cap
$119.1B
P/E ratio
| 2010/12 | 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 143 | 1,411 | 1,527 | 1,212 | 580 | 1,032 | 1,702 | 2,489 | 3,048 | 4,163 | 6,206 | 7,574 | 8,931 | 9,869 | 11,020 |
| Revenue growth (%) | - | ||||||||||||||
| Cost of revenue | - | 64 | 237 | 89 | 40 | 117 | 207 | 273 | 410 | 548 | 736 | 904 | 1,080 | 1,262 | 1,531 |
| Research & development | 637 | 708 | 806 | 919 | 856 | 996 | 1,048 | 1,325 | 1,416 | 1,755 | 1,830 | 3,051 | - | - | - |
| Selling, general & administrative | 188 | 401 | 437 | 362 | 305 | 377 | 433 | 496 | 558 | 658 | 770 | 840 | 945 | 1,137 | 1,464 |
| Operating margin (%) | |||||||||||||||
| Operating income | -696 | 114 | 2 | -903 | -692 | -467 | 10 | 123 | 635 | 1,198 | 2,856 | 2,782 | 4,307 | 3,832 | -233 |
| Operating expenses | 839 | 1,297 | 1,525 | 2,115 | 1,273 | 1,499 | 1,692 | 2,365 | 2,412 | 2,965 | 3,349 | 4,792 | 4,623 | 6,037 | 11,253 |
| Income before tax | - | 60 | -12 | -976 | -735 | -558 | -67 | -16 | 600 | 1,395 | 3,117 | 2,730 | 4,232 | 4,380 | 249 |
| Pretax margin (%) | - | 4.3 | -0.8 | -80.5 | -126.6 | -54 | -4 | -0.6 | 19.7 | 33.5 | 50.2 | 36 | 47.4 | 44.4 | 2.3 |
| Provision for income taxes | - | 19 | 39 | -289 | 7 | 30 | 17 | -107 | -1,487 | 218 | 405 | 388 | 910 | 760 | 784 |
| Effective tax rate (%) | - | ||||||||||||||
| Net income | -755 | 41 | -51 | -445 | -739 | -556 | -84 | 263 | 2,097 | 1,177 | 2,712 | 2,342 | 3,322 | 3,620 | -536 |
| Net income margin (%) | |||||||||||||||
| Earnings per share | -3.77 | 0.14 | -0.5 | -1.98 | -3.14 | -2.31 | -0.46 | 1.06 | 8.24 | 4.58 | 10.44 | 9.09 | 12.97 | 14.05 | -2.08 |
| Diluted EPS | -3.77 | 0.14 | -0.5 | -1.98 | -3.14 | -2.31 | -0.46 | 1.04 | 8.09 | 4.51 | 10.29 | 9.01 | 12.82 | 13.89 | -2.08 |
| EBITDA | |||||||||||||||
| EBITDA margin (%) |